Azacord

Adults w/ all subtypes of myelodysplastic syndrome (MDS).

IV/SC 1st treatment cycle: 75 mg/m² daily for 7 days. Repeat cycles every 4 wk. May be increased to 100 mg/m² if no beneficial effect is seen after 2 treatment cycles & no toxicity other than nausea & vomiting has occurred. Treat patient for min of 4-6 cycles.

Hypersensitivity to azacitidine or mannitol. Patients w/ advanced malignant hepatic tumors.

Anemia, neutropenia & thrombocytopenia. Patients w/ liver disease. Reports of progressive hepatic coma & death during treatment in patients w/ extensive tumor burden due to metastatic disease, especially in those w/ baseline albumin <30 g/L; renal abnormalities ranging from elevated serum creatinine to renal failure & death in patients treated w/ IV azacitidine in combination w/ other chemotherapeutic agents for non-MDS conditions. Perform CBC as needed to monitor response & toxicity, but at min, prior to each dosing cycle; & obtain liver chemistries & serum creatinine prior to initiation of therapy. Reduce/hold dose if unexplained reductions in serum bicarbonate <20 mEq/L or elevations of BUN or serum creatinine occur. May experience undesirable effects eg, fatigue when driving a car or operating machines. Renal & severe pre-existing hepatic impairment. Avoid pregnancy during treatment in women of childbearing potential. Female partners of male patients receiving treatment should not become pregnant. Pregnancy & lactation.

Nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, inj site erythema, constipation, neutropenia, ecchymosis. IV: Petechiae, rigors, weakness & hypokalemia.

Cytotoxic Chemotherapy

L01BC07 - azacitidine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.

Rx